Analyst price target range
Viridian Therapeutics Price Target: $36.75 Average
Direct answer
Viridian Therapeutics's average price target is $36.75.
The verified analyst range runs from $22.00 to $50.00.
The low target implies +17.9%, the high target implies +168%, and the range spans 150.1% of the current price.
Forecast evidence checked October 10, 2026.
Get free Viridian Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $18.66
- Average price target
- $36.75
- High price target
- $50.00
- Low price target
- $22.00
- Low target gap
- +17.9%
- Target upside
- +96.9%
- High target gap
- +168%
- Target range width
- 150.1%
- Consensus rating
- Strong Buy
- Analysts
- 16
- Evidence date
- October 10, 2026
- Valid through
- October 17, 2026
Explore related company data
Read the frequently asked questions.
What is Viridian Therapeutics's average price target?
Viridian Therapeutics's verified average price target is $36.75. The target range is $22.00 to $50.00.
How far are Viridian Therapeutics's low and high targets from the recorded price?
The low target implies +17.9%, while the high target implies +168%.
How many analysts are included in Viridian Therapeutics's consensus?
The verified consensus includes 16 analysts.
How is Viridian Therapeutics's target upside or downside calculated?
The average target of $36.75 is divided by the recorded price of $18.66, then one is subtracted to produce +96.9%. This does not guarantee a future return.
When was Viridian Therapeutics's analyst forecast verified?
The data was verified on 2026-10-10. The dataset is valid through 2026-10-17.